Fabio Piscaglia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1563775/publications.pdf

Version: 2024-02-01

272	28,206	9786	5988
papers	citations	73 h-index	160 g-index

278	278	278	20531
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 182-236.	3.7	6,153
2	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, The, 2018, 391, 1163-1173.	13.7	3,542
3	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall in Der Medizin, 2017, 38, e16-e47.	1.5	659
4	The safety of SonovueÂ® in abdominal applications: Retrospective analysis of 23188 investigations. Ultrasound in Medicine and Biology, 2006, 32, 1369-1375.	1.5	654
5	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver â€“ Update 2012. Ultrasound in Medicine and Biology, 2013, 39, 187-210.	1.5	652
6	The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall in Der Medizin, 2018, 39, e2-e44.	1.5	627
7	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut, 2001, 48, 251-259.	12.1	567
8	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. Seminars in Liver Disease, 2013, 32, 348-359.	3.6	508
9	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology, 2016, 63, 827-838.	7.3	467
10	Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treatment Reviews, 2011, 37, 212-220.	7.7	460
11	Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma. Hepatology, 2005, 42, 27-34.	7.3	410
12	Liver Transplantation for Hepatocellular Carcinoma: Results of Down-Staging in Patients Initially Outside the Milan Selection Criteria. American Journal of Transplantation, 2008, 8, 2547-2557.	4.7	341
13	Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 300-307.	3.7	323
14	Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology, 2011, 54, 2055-2063.	7.3	321
15	Rat liver myofibroblasts and hepatic stellate cells: Different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology, 1999, 117, 1205-1221.	1.3	316
16	What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. Journal of Hepatology, 1997, 27, 979-985.	3.7	256
17	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 2017, 49, 471-483.	0.9	254
18	Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontiÃ¨res meeting 2013. European Radiology, 2015, 25, 3438-3454.	4.5	247

#	Article	IF	Citations
19	Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma â©½3cm. Results of a multicenter Italian survey. Journal of Hepatology, 2013, 59, 89-97.	3.7	241
20	Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology, 2011, 53, 1580-1589.	7.3	229
21	How to perform Contrast-Enhanced Ultrasound (CEUS). Ultrasound International Open, 2018, 04, E2-E15.	0.6	222
22	Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liverâ€“Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound in Medicine and Biology, 2020, 46, 2579-2604.	1.5	210
23	Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transplantation, 2005, 11, 1117-1126.	2.4	204
24	The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Short Version). Ultraschall in Der Medizin, 2018, 39, 154-180.	1.5	196
25	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. Journal of Hepatology, 2018, 68, 485-492.	3.7	195
26	Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression. Liver Transplantation, 2005, 11, 497-503.	2.4	191
27	Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut, 2004, 53, 1020-1023.	12.1	190
28	The Impact of Vascular and Nonvascular Findings on the Noninvasive Diagnosis of Small Hepatocellular Carcinoma Based on the EASL and AASLD Criteria. American Journal of Gastroenterology, 2010, 105, 599-609.	0.4	185
29	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. Journal of Hepatology, 2015, 62, 617-624.	3.7	184
30	Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population. Annals of Surgical Oncology, 2009, 16, 413-422.	1.5	178
31	Antithrombotic treatment with directâ€acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver International, 2017, 37, 694-699.	3.9	178
32	Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: A pilot study. Journal of Hepatology, 2010, 52, 880-888.	3.7	168
33	Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-)fibroblast subpopulations in hepatic tissue repair. Histochemistry and Cell Biology, 1999, 112, 387-401.	1.7	164
34	Acoustic Radiation Force Impulse Elastography for fibrosis evaluation in patients with chronic hepatitis C: An international multicenter study. European Journal of Radiology, 2012, 81, 4112-4118.	2.6	156
35	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 712-723.	0.9	155
36	CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI. Abdominal Radiology, 2018, 43, 127-142.	2.1	147

#	Article	IF	Citations
37	Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long-term prospective study. Hepatology, 1999, 30, 58-64.	7.3	141
38	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver â€“ Update 2020 â€“ WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall in Der Medizin, 2020, 41, 562-585.	1.5	130
39	Response rate and clinical outcome of HCC after first and repeated cTACE performed â€œon demandâ€. Journal of Hepatology, 2012, 57, 1258-1267.	3.7	126
40	Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. Journal of Hepatology, 2004, 41, 421-426.	3.7	122
41	New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut, 2018, 67, 1674-1682.	12.1	114
42	Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2008, 48, 848-857.	3.7	113
43	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Medicine, 2016, 13, e1002006.	8.4	113
44	Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. Journal of Hepatology, 2013, 58, 1188-1193.	3.7	110
45	Contrast Enhanced Ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADSÂ®): the official version by the American College of Radiology (ACR). Ultraschall in Der Medizin, 2017, 38, 85-86.	1.5	110
46	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICEâ€1 study. International Journal of Cancer, 2014, 135, 1247-1256.	5.1	109
47	High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?. Gut, 2007, 56, 237-242.	12.1	108
48	Characterization of Focal Liver Lesions with Contrast-Enhanced Ultrasound. Ultrasound in Medicine and Biology, 2010, 36, 531-550.	1.5	102
49	Impact of gadoxetic acid (Gdâ€<scp>EOB</scp>â€<scp>DTPA</scp>)â€enhanced magnetic resonance on the nonâ€invasive diagnosis of small hepatocellular carcinoma: a prospective study. Alimentary Pharmacology and Therapeutics, 2013, 37, 355-363.	3.7	98
50	Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 â€“ a review of important differences compared to the CT/MRI system. Clinical and Molecular Hepatology, 2017, 23, 280-289.	8.9	96
51	Hepatocellular Carcinoma Responding to Superselective Transarterial Chemoembolization: An Issue of Nodule Dimension?. Journal of Vascular and Interventional Radiology, 2013, 24, 509-517.	0.5	95
52	Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer, 2018, 7, 104-119.	7.7	95
53	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. Hepatology, 2020, 71, 658-669.	7.3	95
54	Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transplantation, 2010, 16, 658-667.	2.4	93

#	Article	IF	Citations
55	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). Ultraschall in Der Medizin, 2017, 38, 377-394.	1.5	93
56	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology, 2018, 67, 1784-1796.	7.3	93
57	Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. Journal of Clinical Oncology, 2020, 38, 478-478.	1.6	93
58	Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transplantation, 2011, 17, 1344-1354.	2.4	91
59	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver International, 2013, 33, 771-779.	3.9	91
60	Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients. Clinical Cancer Research, 2012, 18, 4397-4405.	7.0	87
61	Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdominal Radiology, 2018, 43, 861-879.	2.1	85
62	American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay. Ultraschall in Der Medizin, 2017, 38, 320-324.	1.5	84
63	Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. Journal of Hepatology, 2016, 64, 79-86.	3.7	83
64	Expression of reelin in hepatic stellate cells and during hepatic tissue repair: a novel marker for the differentiation of HSC from other liver myofibroblasts. Journal of Hepatology, 2002, 36, 607-613.	3.7	82
65	Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): Comments on AASLD guidelines. Journal of Hepatology, 2012, 57, 930-932.	3.7	80
66	Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma. Liver Cancer, 2012, 1, 190-200.	7.7	78
67	High prevalence of Helicobacter pylori in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer. Digestive Diseases and Sciences, 1997, 42, 2024-2030.	2.3	77
68	Systematic review of surgical resectionvsradiofrequency ablation for hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 4106.	3.3	77
69	The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study. Digestive and Liver Disease, 2013, 45, 762-768.	0.9	76
70	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clinical and Experimental Immunology, 2016, 185, 61-71.	2.6	75
71	New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. Digestive and Liver Disease, 2007, 39, 187-195.	0.9	74
72	Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transplantation, 2009, 15, 782-789.	2.4	74

#	Article	IF	Citations
73	Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110169.	3.2	74
74	Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: Usefulness of transient elastography. Digestive and Liver Disease, 2009, 41, 217-225.	0.9	71
75	Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. Gut, 2007, 56, 253-258.	12.1	70
76	A metaâ€analysis of single <scp>HCV</scp>â€untreated arm of studies evaluating outcomes after curative treatments of <scp>HCV</scp>â€related hepatocellular carcinoma. Liver International, 2017, 37, 1157-1166.	3.9	70
77	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <scp>HCV</scp> eradication does not depend on the use of interferon. Alimentary Pharmacology and Therapeutics, 2017, 45, 160-168.	3.7	70
78	When to perform hepatic resection for intermediateâ€stage hepatocellular carcinoma. Hepatology, 2015, 61, 905-914.	7.3	69
79	The changing scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2021, 41, 585-597.	3.9	69
80	Characterization of liver lesions by real-time contrast-enhanced ultrasonography. European Journal of Gastroenterology and Hepatology, 2007, 19, 3-14.	1.6	68
81	Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A metaâ€analysis of randomized trials. United European Gastroenterology Journal, 2017, 5, 511-518.	3.8	67
82	Value of splanchnic Doppler ultrasound in the diagnosis of portal hypertension. Ultrasound in Medicine and Biology, 2001, 27, 893-899.	1.5	66
83	Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2017, 35, 4001-4001.	1.6	65
84	Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer, 2007, 7, 171.	2.6	64
85	Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. Journal of Hepatology, 2019, 71, 1175-1183.	3.7	64
86	Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Digestive and Liver Disease, 2015, 47, 518-522.	0.9	63
87	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. Ultrasound in Medicine and Biology, 2021, 47, 2803-2820.	1.5	63
88	Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 995-1001.	3.7	61
89	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. American Journal of Gastroenterology, 2016, 111, 70-77.	0.4	59
90	A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. European Journal of Gastroenterology and Hepatology, 2019, 31, 34-42.	1.6	58

#	Article	IF	Citations
91	The role of ultrasound elastographic techniques in chronic liver disease: Current status and future perspectives. European Journal of Radiology, 2014, 83, 450-455.	2.6	57
92	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group. Digestive and Liver Disease, 2014, 46, 549-555.	0.9	57
93	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.9	57
94	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. Gut, 2023, 72, 141-152.	12.1	57
95	Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. European Radiology, 2018, 28, 3611-3620.	4.5	55
96	Intra- and extrahepatic arterial resistances in chronic hepatitis and liver cirrhosis. Ultrasound in Medicine and Biology, 1997, 23, 675-682.	1.5	54
97	Safety of Ultrasound Contrast Agents in Patients With Known or Suspected Cardiac Shunts. American Journal of Cardiology, 2013, 112, 1039-1045.	1.6	53
98	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. Digestive and Liver Disease, 2010, 42, S258-S263.	0.9	51
99	Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. Digestive and Liver Disease, 2017, 49, 802-808.	0.9	51
100	Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. European Journal of Gastroenterology and Hepatology, 2006, 18, 1255-1261.	1.6	48
101	Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. Molecular Imaging and Biology, 2015, 17, 29-37.	2.6	48
102	Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer, 2019, 19, 795.	2.6	48
103	TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. Journal of Personalized Medicine, 2021, 11, 1041.	2.5	48
104	The ART Score Is Not Effective to Select Patients for Transarterial Chemoembolization Retreatment in an Italian Series. Digestive Diseases, 2014, 32, 711-716.	1.9	47
105	MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Research, 2020, 80, 1720-1734.	0.9	47
106	Cellular localization of hepatic cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines. Biochemical Pharmacology, 1999, 58, 157-165.	4.4	46
107	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Liver International, 2017, 37, 423-433.	3.9	46
108	Benefits, Open questions and Challenges of the use of Ultrasound inÂthe COVID-19 pandemic era. The views of a panel of worldwide international experts. Ultraschall in Der Medizin, 2020, 41, 228-236.	1.5	46

#	Article	IF	Citations
109	Assessment of Vascular Patterns of Small Liver Mass Lesions: Value and Limitation of The Different Doppler Ultrasound Modalities. American Journal of Gastroenterology, 2000, 95, 3537-3546.	0.4	45
110	A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. Liver Transplantation, 2007, 13, 857-866.	2.4	45
111	Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances. Current Pharmaceutical Design, 2012, 18, 2236-2252.	1.9	45
112	Lenvatinib versus sorafenib in firstâ€line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver International, 2021, 41, 1389-1397.	3.9	45
113	Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. Journal of Hepatology, 2005, 43, 310-316.	3.7	44
114	Long-term effectiveness of Radiofrequency Ablation for solitary small Hepatocellular Carcinoma: A retrospective analysis of 363 patients. Digestive and Liver Disease, 2013, 45, 336-341.	0.9	44
115	An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Digestive and Liver Disease, 2014, 46, 257-263.	0.9	43
116	Vascularity of liver tumours and recent advances in Doppler ultrasound. Journal of Hepatology, 2001, 34, 474-482.	3.7	42
117	Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology, 2001, 34, 608-608.	7.3	41
118	In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. Journal of Hepatology, 2003, 39, 997-1003.	3.7	40
119	Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. Clinical Cancer Research, 2021, 27, 4848-4858.	7.0	39
120	Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology, 2000, 31, 349-357.	7.3	37
121	Extracorporeal Detoxification for Hepatic Failure Using Molecular Adsorbent Recirculating System: Depurative Efficiency and Clinical Results in a Longâ€Term Followâ€Up. Artificial Organs, 2014, 38, 125-134.	1.9	37
122	Hepatorenal syndrome: Update on diagnosis and treatment. World Journal of Nephrology, 2015, 4, 511.	2.0	37
123	A benign tumour of the liver mimicking malignant liver disease â€“ cholangiocellular adenoma. Scandinavian Journal of Gastroenterology, 2009, 44, 633-636.	1.5	36
124	TACE performed in patients with a single nodule of Hepatocellular Carcinoma. BMC Cancer, 2014, 14, 601.	2.6	36
125	Role of Contrast-Enhanced Ultrasonography in Primary Hepatic Lymphoma. Journal of Ultrasound in Medicine, 2010, 29, 1353-1356.	1.7	35
126	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data metaâ€analysis. Liver International, 2020, 40, 1435-1446.	3.9	35

#	Article	IF	Citations
127	The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 1185-1198.	3.7	35
128	Superior mesenteric artery impedance in chronic liver diseases: relationship with disease severity and portal circulation. American Journal of Gastroenterology, 1998, 93, 1925-1930.	0.4	32
129	Treatment of hepatocellular carcinoma in Child-Pugh B patients. Digestive and Liver Disease, 2013, 45, 852-858.	0.9	32
130	Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers, 2020, 12, 794.	3.7	32
131	CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis. Radiology, 2022, 302, 326-335.	7.3	32
132	Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity. European Journal of Gastroenterology and Hepatology, 1997, 9, 799-804.	1.6	31
133	Imaging of combined hepatocellularâ€cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. United European Gastroenterology Journal, 2019, 7, 69-77.	3.8	31
134	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 370-379.	7.7	31
135	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. Cancer Management and Research, 2021, Volume 13, 9379-9389.	1.9	31
136	Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases. Hepatitis Monthly, 2013, 13, e11721.	0.2	29
137	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	2.5	29
138	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 741-757.	3.7	29
139	Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology, 2003, 34, 608-608.	7.3	27
140	Expression of ECM proteins fibulin-1 and -2 in acute and chronic liver disease and in cultured rat liver cells. Cell and Tissue Research, 2009, 337, 449-462.	2.9	27
141	A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2017, 18, 1134.	4.1	27
142	Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).. Journal of Clinical Oncology, 2019, 37, 317-317.	1.6	26
143	Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Digestive and Liver Disease, 2019, 51, 1067-1073.	0.9	25
144	MicroRNAs in Animal Models of HCC. Cancers, 2019, 11, 1906.	3.7	25

#	Article	IF	Citations
145	European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Policy Document Development Strategy â€“ Clinical Practice Guidelines, Position Statements and Technological Reviews. Ultrasound International Open, 2019, 05, E2-E10.	0.6	24
146	EUS Needle Identification Comparison and Evaluation study (withÂvideos). Gastrointestinal Endoscopy, 2016, 84, 424-433.e2.	1.0	23
147	Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness. Journal of Ultrasound, 2017, 20, 213-225.	1.3	23
148	Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British Journal of Cancer, 2019, 121, 218-221.	6.4	22
149	Hemodynamics in focal nodular hyperplasia. Journal of Hepatology, 1999, 31, 576.	3.7	21
150	Validation of noninvasive methods for the assessment of liver fibrosis in patients with recurrent hepatitis C after transplantation. Liver Transplantation, 2010, 16, 1006-1007.	2.4	21
151	Quantification of enhancement of focal liver lesions during contrast-enhanced ultrasound (CEUS). Analysis of ten selected frames is more simple but as reliable as the analysis of the entire loop for most parameters. European Journal of Radiology, 2012, 81, 709-713.	2.6	21
152	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers, 2021, 13, 1673.	3.7	21
153	Single hepatocellular carcinoma smaller than 2 cm: are ethanol injection and radiofrequency ablation equally effective?. Anticancer Research, 2015, 35, 325-32.	1.1	21
154	Malignancies in primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology, 2008, 20, 1-4.	1.6	20
155	Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediateâ€“advanced hepatocellular carcinoma. Future Oncology, 2015, 11, 3133-3142.	2.4	20
156	Imaging Diagnosis of Hepatocellular Carcinoma: Recent Advances of Contrast-Enhanced Ultrasonography with SonoVueÂ®. Liver Cancer, 2016, 5, 55-66.	7.7	20
157	Detection of HCV antigens in liver graft: Relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transplantation, 2006, 12, 1673-1681.	2.4	19
158	Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. Digestive Diseases, 2015, 33, 735-744.	1.9	19
159	Caution in the use of boldo in herbal laxatives: A case of hepatotoxicity. Scandinavian Journal of Gastroenterology, 2005, 40, 236-239.	1.5	18
160	Recent advances in the diagnosis of hepatocellular carcinoma. Hepatology Research, 2007, 37, S178-92.	3.4	18
161	Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy?. Clinical Transplantation, 2009, 23, 519-524.	1.6	18
162	Bidimensional shear wave ultrasound elastography with supersonic imaging to predict presence of oesophageal varices in cirrhosis. Liver International, 2017, 37, 1405-1405.	3.9	18

#	Article	IF	Citations
163	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. Liver Cancer, 2017, 6, 337-348.	7.7	18
164	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. Scientific Reports, 2019, 9, 3781.	3.3	18
165	Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation, 2021, 51, e13542.	3.4	18
166	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver International, 2021, 41, 2997-3008.	3.9	18
167	Circadian occurrence of variceal bleeding in patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 1115-1120.	2.8	17
168	Influence of Esophageal Varices and Spontaneous Portal-Systemic Shunts on Postprandial Splanchnic Hemodynamics. American Journal of Gastroenterology, 2001, 96, 550-556.	0.4	17
169	Diagnosis of Hepatocellular Carcinoma with Non-Invasive Imaging: a Plea for Worldwide Adoption of Standard andÂPrecise Terminology for Describing Enhancement Criteria. Ultraschall in Der Medizin, 2017, 38, 9-11.	1.5	16
170	Reader agreement and accuracy of ultrasound features for hepatic steatosis. Abdominal Radiology, 2019, 44, 54-64.	2.1	16
171	Liver metastases from rectal carcinoma: Disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy. Journal of Clinical Ultrasound, 2003, 31, 387-391.	0.8	15
172	Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis. Liver Cancer, 2020, 9, 744-755.	7.7	15
173	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. Clinical and Translational Gastroenterology, 2021, 12, e00286.	2.5	15
174	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 477-492.	3.7	15
175	A new horizon in the prevention of the postembolization syndrome after transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatology, 2018, 67, 467-469.	7.3	13
176	Different techniques for ultrasound liver elastography. Journal of Hepatology, 2019, 70, 545-547.	3.7	13
177	Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma. Cancers, 2020, 12, 2674.	3.7	13
178	Contrast-Enhanced Ultrasound LI-RADS LR-5 in Hepatic Tuberculosis: Case Report and Literature Review of Imaging Features. Gastroenterology Insights, 2021, 12, 1-9.	1.2	13
179	Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. Cells, 2021, 10, 521.	4.1	13
180	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. Journal of Clinical Medicine, 2021, 10, 3201.	2.4	13

#	Article	IF	Citations
181	Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders. Cancers, 2021, 13, 6376.	3.7	13
182	Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, 729-734.	0.9	12
183	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785.	3.6	12
184	Time to Clarify Common Misconceptions about the Liver Imaging Reporting and Data System for Contrast-enhanced US. Radiology, 2020, 295, 245-247.	7.3	12
185	MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 369-385.	3.7	12
186	Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis. Internal and Emergency Medicine, 2016, 11, 19-30.	2.0	11
187	Duplex Doppler findings in splenic arteriovenous fistula. , 1998, 26, 103-105.		10
188	Liver cirrhosis, ascites, and hyperfibrinolysis. American Journal of Gastroenterology, 2001, 96, 3222-3222.	0.4	10
189	Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis. Clinical Gastroenterology and Hepatology, 2006, 4, 1395-1402.	4.4	10
190	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, 1015-1021.	0.9	10
191	Utilityâ€based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alphaâ€fetoprotein model as a survival predictor. Liver Transplantation, 2015, 21, 1250-1258.	2.4	10
192	Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma. Liver International, 2018, 38, 278-284.	3.9	10
193	Monofocal hepatocellular carcinoma: How much does size matter?. Liver International, 2021, 41, 396-407.	3.9	10
194	The Perceived Ability of Gastroenterologists, Hepatologists and Surgeons Can Bias Medical Decision Making. International Journal of Environmental Research and Public Health, 2020, 17, 1058.	2.6	10
195	Hepatocellular carcinoma in the non-cirrhotic liver. Clinical Hemorheology and Microcirculation, 2022, 80, 423-436.	1.7	10
196	Doppler evaluation of the effects of pharmacological treatment of portal hypertension. Ultrasound in Medicine and Biology, 1999, 25, 923-932.	1.5	9
197	Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver. Magnetic Resonance Imaging, 2021, 75, 9-20.	1.8	9
198	Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoproteinâ€‰â‰¥â€‰400Âng/mL: A Matching-Adjusted Indirect Comparison. Advances in Therapy, 2021, 38, 2472-2490.	2.9	9

#	Article	IF	Citations
199	Genetics in Familial Intrahepatic Cholestasis: Clinical Patterns and Development of Liver and Biliary Cancers: A Review of the Literature. Cancers, 2022, 14, 3421.	3.7	9
200	Outcomes from a program of home care attendance in very frail elderly subjects. Archives of Gerontology and Geriatrics, 2007, 44, 95-103.	3.0	8
201	Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: Some enthusiasm with a word of caution. Journal of Hepatology, 2013, 59, 924-925.	3.7	8
202	Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. Bone Marrow Transplantation, 2018, 53, 591-599.	2.4	8
203	Contrast-enhanced harmonic endoscopic ultrasound-guided ethanol injection for a small hepatocellular carcinoma. Endoscopy, 2019, 51, E317-E318.	1.8	8
204	Artificial Intelligence: What Is It and How Can It Expand theÂUltrasound Potential in the Future?. Ultraschall in Der Medizin, 2020, 41, 356-360.	1.5	8
205	Contrast-Enhanced Ultrasound: Development of Syllabus for Core Theoretical and Practical Competencies. Ultrasound in Medicine and Biology, 2020, 46, 2287-2292.	1.5	8
206	Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study). Journal of Nephrology, 2021, 34, 77-88.	2.0	8
207	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. International Journal of Biological Markers, 2021, 36, 54-61.	1.8	8
208	Cirrhosis does not shift the circadian phase of plasma fibrinolysis. American Journal of Gastroenterology, 2002, 97, 1512-1517.	0.4	7
209	Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma. BMC Cancer, 2014, 14, 403.	2.6	7
210	Ablation for hepatocellular carcinoma: beyond the standard indications. Medical Oncology, 2020, 37, 23.	2.5	7
211	Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2020, 26, 3909-3914.	1.9	7
212	Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, 2022, 14, 2493.	4.1	7
213	Intrahepatic artery pseudoaneurysm: A possible complication of blind thoracentesis. , 1999, 27, 151-155.		6
214	Hepatic artery thrombosis and graft ischemia in the presence of preserved arterial inflow: Not a contradiction but a real possibility. Liver Transplantation, 2004, 10, 710-711.	2.4	6
215	Contrast Enhanced Ultrasonography for the Evaluation of Coil Embolization of Splenic Artery Aneurysm. Circulation, 2010, 122, e451-4.	1.6	6
216	DAAs for HCV and risk of hepatocellular carcinoma: current standpoint. The Lancet Gastroenterology and Hepatology, 2018, 3, 736-738.	8.1	6

#	Article	IF	Citations
217	SIUMB recommendations for focal pancreatic lesions. Journal of Ultrasound, 2020, 23, 599-606.	1.3	6
218	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. Journal of Gastroenterology, 2021, 56, 570-580.	5.1	6
219	An Uncommon Focal Liver Lesion: Intrahepatic Splenosis. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 257-262.	0.9	6
220	Pattern of progression of intrahepatic cholangiocarcinoma: Implications for secondâ€line clinical trials. Liver International, 2022, 42, 458-467.	3.9	6
221	Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area. Nutrients, 2022, 14, 1652.	4.1	6
222	Allelic imbalance on 16q in small, unifocal hepatocellular carcinoma: correlation with HBV and HCV infections and cellular proliferation rate. Digestive Diseases and Sciences, 2000, 45, 306-311.	2.3	5
223	Ongoing challenges in the diagnosis of hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2016, 10, 451-463.	3.0	5
224	Contrast-enhanced ultrasound of the liver in colorectal cancer: AÂuseful tool in the right patient. Journal of Hepatology, 2021, 74, 272-273.	3.7	5
225	Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for COVID-19 Pandemic. Diagnostics, 2021, 11, 82.	2.6	5
226	Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5). Cancers, 2022, 14, 336.	3.7	5
227	Nodule in Nodule: Malignant Transformation of a Macroregenerative Nodule in Cirrhosis Revealed by Duplex-Doppler. Journal of Hepatology, 1999, 30, 955.	3.7	4
228	Effect of LevovistÂ® on splanchnic hemodynamics in cirrhotic patients. Ultrasound in Medicine and Biology, 2003, 29, 643-648.	1.5	4
229	Onset of bronchiolitis obliterans organizing pneumonia in a liver transplant recipient under peg-interferon and ribavirin treatment. Internal and Emergency Medicine, 2008, 3, 77-80.	2.0	4
230	Widen NomoGram for multinomial logistic regression: an application to staging liver fibrosis in chronic hepatitis C patients. Statistical Methods in Medical Research, 2017, 26, 823-838.	1.5	4
231	Non-enhanced MRI surveillance for HCC: A new tool for all, none or selected patients at risk?. Journal of Hepatology, 2020, 72, 607-609.	3.7	4
232	Retrospective analysis of safety of ultrasound-guided percutaneous liver biopsy in the 21st century. European Journal of Gastroenterology and Hepatology, 2021, 33, e355-e362.	1.6	4
233	Tocilizumab: From Rheumatic Diseases to COVID-19. Current Pharmaceutical Design, 2021, 27, 1597-1607.	1.9	4
234	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. Hepatology Research, 2021, 51, 796-802.	3.4	4

#	Article	IF	Citations
235	Surveillance for hepatocellular carcinoma with a 3-months interval in â€œextremely high-riskâ€•patients does not further improve survival. Digestive and Liver Disease, 2022, 54, 927-936.	0.9	4
236	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. European Journal of Cancer, 2021, 158, 133-143.	2.8	4
237	Diagnosis of Cirrhosis and Portal Hypertension. American Journal of Gastroenterology, 1998, 93, 1598-1599.	0.4	3
238	Selecting patients with hepatocellular carcinoma for transplantation. Liver Transplantation, 2007, 13, 1203-1203.	2.4	3
239	Field practice studies on sorafenib: Lessons in systemic treatment of hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 367-368.	0.9	3
240	Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. European Journal of Gastroenterology and Hepatology, 2013, 25, 1385-1395.	1.6	3
241	Imaging of Liver Tumors in Patients with Chronic Liver Disease. Current Radiology Reports, 2014, 2, 1.	1.4	3
242	What Ultrasound Operators Must Be Well Aware of in a World With Raising Burden of Non Alcoholic Fatty Liver Disease?. Ultraschall in Der Medizin, 2019, 40, 7-10.	1.5	3
243	Clinical Practice Guidance and Education in Ultrasound: Evidence and experience are two sides of one coin!. Ultraschall in Der Medizin, 2022, 43, 7-11.	1.5	3
244	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digestive and Liver Disease, 2022, 54, 1215-1221.	0.9	3
245	A case of extracranial vertebral artery dissection with spontaneous recovery. European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology, 1997, 6, 197-201.	1.3	2
246	Use of perfusional angiosonography in liver transplantation and conservative management of post-transplant intra-hepatic pseudo-aneurysm. Transplant International, 2004, 17, 634-638.	1.6	2
247	Down-Staging of Hepatocellular Carcinoma Before Liver Transplantation: Should We Change Our Clinical Practice?. Annals of Surgery, 2009, 250, 348.	4.2	2
248	â€œSurvival benefitâ€• The final destination, with still a long way to go. Digestive and Liver Disease, 2010, 42, 608-610.	0.9	2
249	Yttrium 90 radioembolization: The horizon is changing for patients with intermediate and advanced hepatocellular carcinoma. Hepatology, 2013, 57, 1694-1696.	7.3	2
250	Natural history of nonalcoholic steatohepatitisâ€“associated hepatocellular carcinoma. Clinical Liver Disease, 2016, 8, 105-107.	2.1	2
251	Reply to Anticoagulation for Portal Vein Thrombosis in Cirrhosis. American Journal of Gastroenterology, 2019, 114, 1001-1002.	0.4	2
252	Liver Imaging Reporting and Data System: Review of Pros and Cons. Seminars in Liver Disease, 2022, 42, 104-111.	3.6	2

#	Article	IF	Citations
253	Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs. Translational Cancer Research, 2019, 8, S223-S232.	1.0	2
254	Efficacy of a short course of lung ultrasound for primary care physicians in the assessment of COVID-19-positive patients. Family Practice, 2022, 39, 656-661.	1.9	2
255	Contrastâ€Enhanced Ultrasound (<scp>CEUS</scp>) in the Evaluation of Hemoperitoneum in Patients With Cirrhosis. Journal of Ultrasound in Medicine, 2022, , .	1.7	2
256	Splanchnic arterial doppler parameters in portal hypertension. Hepatology, 1999, 29, 1610-1610.	7.3	1
257	Portal pressure and Doppler. Ultrasound in Medicine and Biology, 2003, 29, 495-496.	1.5	1
258	Down-staging of hepatocellular carcinoma prior to liver transplantation: The power of selection. Hepatology, 2009, 49, 1056-1056.	7.3	1
259	Contrast Enhanced Imaging Pattern of Central Scar in Focal Nodular Hyperplasia. Ultrasound in Medicine and Biology, 2010, 36, 2146-2147.	1.5	1
260	Anticoagulation in Cirrhotic Portal Vein Thrombosis: No Harm, but Survival Benefit Still Unclear. American Journal of Gastroenterology, 2020, 115, 145-146.	0.4	1
261	The expanding potential of functional liver imaging: From research tools to clinical practice in oncology and internal medicine. European Journal of Internal Medicine, 2020, 79, 23-24.	2.2	1
262	Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?. Liver Cancer, 2021, 10, 1-2.	7.7	1
263	Indications for Liver Transplantation. , 2015, , 97-125.		1
264	Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3â€“5 cm. Hepatology, 2022, 76, 6-8.	7.3	1
265	E<scp>ditorial</scp>: Cigarette smoking, abdominal blood flow and abdominal diseases. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 995-996.	2.8	0
266	Use of perfusional angiosonography in liver transplantation and conservatve management of post-transplant intra-hepatie pseudo-aneurysm. Transplant International, 2004, 17, 634-638.	1.6	0
267	Clinico-Pathological Classification. , 2005, , 75-83.		0
268	Reply to: â€œNon-invasive diagnosis of small nodules in cirrhosisâ€• Journal of Hepatology, 2013, 59, 1361-1362.	3.7	0
269	Assessment of long-term prognosis at detection of early hepatocellular carcinoma remains unsolved. Journal of Hepatology, 2014, 61, 1438.	3.7	0
270	Ultrasound Elastography: General and Technical Overview. , 2018, , 83-94.		0

#	Article	IF	Citations
271	Ultrasound in the Assessment of Tumor Response in the Age of Targeted and Immuno-Oncology Therapies. Back to the Future. Ultraschall in Der Medizin, 2019, 40, 129-131.	1.5	0
272	Clinical predictors of response to sorafenib in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, e15149-e15149.	1.6	0